|
Published by: Global Markets Direct
Published: Jul. 31, 2012 - 84 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- AIDS - Related Lymphoma Overview
- Therapeutics Development
- An Overview of Pipeline Products for AIDS - Related Lymphoma
- AIDS - Related Lymphoma Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- AIDS - Related Lymphoma Therapeutics – Products under Investigation by Universities/Institutes
- AIDS - Related Lymphoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Doxil + Methotrexate + Prednisone + Vincristine Sulfate + Sargramostim - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- cART + R-EPOCH - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CHOP-BLEO + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FLEP + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ASHAP + IMVP16 + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Methotrexate + Zidovudine + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Filgrastim + Cyclophosphamide + Cytarabine + Methotrexate + Pegylated Liposomal Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BCNU + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Cell Transplantation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- R-EPOCH + cART - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Sunitinib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine Hydrochloride + Radiation Therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ProMACE-CytaBOM + TMP-SMX + G-CSF + Radiation therapy - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bleomycin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Filgrastim + Rituximab + Sargramostim + Cyclophosphamide + Doxil + Prednisone + Vincristine Sulfate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rituximab + EPOCH - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rituximab + EPOCH + Vorinostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- R-CHOP - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- R-CHOP + Vorinostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Etoposide + Methylprednisolone Sodium Succinate + Carboplatin + AraC + Rituximab + MCNU + L-PAM + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CHOP + Rituximab + Peripheral Blood Stem Cell Transplantation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HAART + Methotrexate + Rituximab + Leucovorin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Velcade + Carboplatin + Dexamethasone + Etoposide + Ifosfamide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Fludarabine + Busulfan + Melphalan + Cyclophosphamide + Total Body Irradiation + Allogeneic Hematopoietic Cell Transplantation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AIDS - Related Lymphoma Therapeutics – Drug Profile Updates
- AIDS - Related Lymphoma Therapeutics – Discontinued Products
- AIDS - Related Lymphoma Therapeutics - Dormant Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for AIDS - Related Lymphoma, H2 2012
- Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- AIDS - Related Lymphoma Therapeutics – Drug Profile Updates
- AIDS - Related Lymphoma Therapeutics – Discontinued Products
- AIDS - Related Lymphoma Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for AIDS - Related Lymphoma, H2 2012
- Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractAIDS - Related Lymphoma – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'AIDS - Related Lymphoma - Pipeline Review, H2 2012', provides an overview of the AIDS - Related Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Lymphoma. 'AIDS - Related Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for AIDS - Related Lymphoma.
- A review of the AIDS - Related Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the AIDS - Related Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for AIDS - Related Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding AIDS - Related Lymphoma pipeline depth and focus of AIDS - Related Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
